Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,232 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Aggressive Behavior in Fragile X Syndome
Interventions: SRX246, Placebo; Drug
Lead sponsor: Azevan Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Cincinnati, Ohio

Conditions: Prostate Cancer
Interventions: Exercise; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Talaromycosis
Interventions: Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: PTSD - Post Traumatic Stress Disorder, TBI-Traumatic Brain Injury
Interventions: Adapted STAIR-NT; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Forest Lake, Minnesota

Conditions: Acne Vulgaris on the Face
Interventions: DispersinB Acne Cleanser; Device
Lead sponsor: Kane Biotech Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
Interventions: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection; Drug · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sanfilippo Syndrome (MPS III)
Interventions: rAAV9-CMV-hNAGLUop; Biological
Lead sponsor: NeuroGT; Industry
Eligibility: 6 Months and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Parkinson's Disease With Freezing of Gait
Interventions: CueStim; Device
Lead sponsor: Fortis Medical Devices Limited; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Boca Raton, Florida • Daytona Beach, Florida • Atlanta, Georgia + 3 more

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain Assessment, VATS, Music Therapy
Interventions: Music Therapy with over-the ear headphones; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
Interventions: Apraclonidine 1.0% ophthalmic solution; Drug
Lead sponsor: Retina Consultants of Delmarva; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: Crohn's Disease, Ulcerative Colitis (UC), Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
Interventions: Empowered Relief, Living Better with Chronic Pain; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clostridium Difficile Infection
Interventions: FZ002, Placebo for FZ002; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Acute Ischemic Stroke
Interventions: Intravenous tenecteplase (TNK), Placebo; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Colorectal Cancer (Diagnosis), Adenoma
Interventions: S-Adenosylmethionine (SAMe); Drug
Lead sponsor: Jun Gong, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Mast Cell Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Fludarabine, Total-Body Irradiation; Biological · Procedure · Drug + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes
Interventions: Social Determinants of Health (SDOH) Screening and Referral; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Up to 21 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neuropathic Corneal Pain
Interventions: Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution; Drug · Other
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Low Back Pain
Interventions: Active Neurolumen, Inactive Neurolumen; Device
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Pain, Postoperative
Interventions: AirSeal Insufflation system, DV5 Insufflation system; Device
Lead sponsor: SurgiQuest, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Binge Eating, Binge Eating Behaviour, Binge Eating/Loss of Control Eating, Body Image, Body Image Disturbance
Interventions: Assessment-only, values-based reflection and goal-setting/action-planning exercises, Minimal-Assessment Control; Behavioral
Lead sponsor: Taylor Rezeppa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Chronic Nausea
Interventions: UROStim; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Training on Systemic and Organ Spec. PM in PC

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Adaptation of the STAIR-NT for First Responders

Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB

Terazosin And Metabolic Engagement in Alzheimer's Disease

Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease

Vascular Effects of SGLT2i in Non-diabetic CKD

Implementing Music Therapy for Video-Assisted Thoracoscopic Surgery Patients: A Quality Improvement Initiative

Psilocybin-Assisted Therapy as a Treatment for Depression

Iopidine to Decrease Intraocular Pressure Rise After Injections

Online Pain Education for Crohn's Disease and Ulcerative Colitis

A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile

Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant

S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas

Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome

Screening For Social Determinants Of Health In Routine Diabetes Care

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

Treatment of Chronic Lower Back Pain With a Combination of Electrical Stimulation, LED, and Laser Therapy

Comparison of AirSeal to DV5 Insufflation in Gastric Sleeve Procedures - The "CAT5-GS" Study

Testing SHAPE: A Single-Session Intervention Targeting Binge Eating in Women Through Assessment and Values-Based Strategies

Vagal Auricular Stimulation for Motion Sickness